Clinical trials: Substance Use Disorder
Alcohol Use Disorder
A Study of Brenipatide in Participants With Alcohol Use Disorder
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use.
- Trial name
- RENEW-ALC-2 (NCT07219953)
- Testing
- LY3537031
- Where
- 116 sites in United States, Belgium and 6 more
- Volunteers
- 1,100 people
- Sponsor
- Eli Lilly and Company
Tobacco Use, Nicotine Dependence, Other Tobacco Product
A Study to Characterize Puff Topography With Use of JUUL 5% Electronic Nicotine Delivery Systems (ENDS) in Adult Smokers
A Study to Characterize Puff Topography with Use of a JUUL 5% Electronic Nicotine Delivery Systems (ENDS) in Adult Smokers
- Conditions
- Tobacco Use, Nicotine Dependence, Other Tobacco Product, Tobacco Smoking
- Trial name
- NCT03596034
- Testing
- JUUL 5%, Virginia Tobacco, ENDS product
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.
Opioid Use Disorder
A Stepped-Wedge Cluster Randomized Trial of a Digital App to Support Medication-Assisted Treatment in Individuals With Opioid Use Disorder
The goal of this clinical trial is to learn if a mobile health app called Recovery Connect can help people stay in treatment for opioid use disorder.
- Trial name
- SMART-OUD (NCT07140926)
- Testing
- Recovery Connect
- Where
- 9 sites in United States
- Volunteers
- 1,524 people
- Sponsor
- Bright Therapeutics
Tobacco Dependence
Pharmacokinetics With Two New Oral Nicotine Replacement Products and Nicorette® Gum
Single-dose pharmacokinetics with two new oral nicotine replacement products and Nicorette® gum.
- Trial name
- NCT01152723
- Testing
- Nicotine
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- McNeil AB
Schizophrenia, Alcohol Use Disorder
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
This double-blind, randomized study will evaluate the efficacy, safety and tolerability of ALKS 3831 in subjects with schizophrenia and alcohol use disorder (AUD).
- Trial name
- NCT02161718
- Testing
- Samidorphan + olanzapine (ALKS 3831)
- Where
- 71 sites in United States, Bulgaria and 1 more
- Volunteers
- 300 people
- Sponsor
- Alkermes, Inc.
Thromboangiitis Obliterans (Buerger's Disease)
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the…
- Trial name
- NCT07215923
- Testing
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Antidote Therapeutics, Inc
Personality
Personality and Drug Use (PDU)
The study aims to assess whether the use of drugs relates to personality ratings. Specifically, we plan to investigate if people with different histories of substance use differentiate on personality assessments (current and…
- Trial name
- PDU (NCT05180149)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Quantified Citizen Technologies Inc.
Alcohol Dependence, Alcohol Interaction
Clinical Trial to Evaluate the Safety of PT150 (Formerly ORG34517) When it is Taken Concurrently With Alcohol
The purpose of the clinical study is to compare pharmacodynamic and safety endpoints following an alcohol challenge prior to and concurrent with PT150 (study drug) treatment.
- Trial name
- NCT03548714
- Testing
- PT150, Beverage
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Pop Test Oncology LLC
Alcohol Use Disorder (AUD)
A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder
TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects and has been found to be safe and tolerated at doses predicted to be efficacious…
- Trial name
- LIBERATE-A (NCT06648655)
- Testing
- TMP-301
- Where
- 14 sites in United States
- Volunteers
- 110 people
- Sponsor
- Tempero Bio, Inc.
Substance Use Disorder, Drug Dependence,
Impact of Prevention Awareness Group (PAG) on Treatment Attendance and Drug Abstinence Among Substance User
Substance Use Disorder has been showing a rising trend all over the world including India. The project tested whether a Integrated community wide effort of Prevention and Awareness Groups (PAG) to manage substance use would have…
- Conditions
- Substance Use Disorder, Drug Dependence,, Alcohol Dependence
- Trial name
- NCT02173041
- Testing
- Prevention Awareness Groups (PAG), Standard Care
- Where
- India
- Volunteers
- 152 people
- Sponsor
- Macmillan Research Group UK
Tobacco Dependence
Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy
The purpose of this study is to assess the efficacy and safety of a novel nicotine product for continuous abstinence from smoking.
- Trial name
- NCT02355665
- Testing
- Nicotine Spray
- Where
- 8 sites in United States
- Volunteers
- 1,198 people
- Sponsor
- McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Opioid Use Disorder
Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)
This study will evaluate the safety, effectiveness and tolerance of low doses of oral naltrexone along with buprenorphine to treat opioid use disorder prior to the first injection of VIVITROL.
- Trial name
- NCT02537574
- Testing
- NTX/BUP, NTX/PBO-B, PBO-N/PBO-B
- Where
- 20 sites in United States
- Volunteers
- 380 people
- Sponsor
- Alkermes, Inc.
Opioid-use Disorder, Opioid Misuse
Comparing a Patient Self-Assessment Software to Treatment as Usual in Opioid Prescriber and Patient Opioid Outcomes
The Care Continuity Program (CCP), a product of Sure Med Compliance, is a novel, online patient self-assessment used by prescribers of opioids to better identify patient risk factors and therapy benefit.
- Conditions
- Opioid-use Disorder, Opioid Misuse, Opioid Use, Chronic Pain
- Trial name
- NCT04945525
- Testing
- Care Continuity Program
- Where
- United States
- Volunteers
- 1,840 people
- Sponsor
- Sure Med Compliance
Substance Use Disorder (SUD)
Research and Engagement on Substance Use: Harnessing Awareness and Personalized Education (RESHAPE) to Improve Well-being and Self-efficacy
The goal of the RESHAPE study is to learn about the needs and experiences of adults who report having, or being at risk for, substance use disorder.
- Trial name
- RESHAPE (NCT06952491)
- Where
- United States
- Volunteers
- 1,910 people
- Sponsor
- Evidation Health
Alcohol Use Disorder
Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder
This study is aimed at examining whether GET73 modulates the indices of central glutamate and γ-aminobutyric acid (GABA) levels in recently abstinent subjects that meet Alcohol Use Disorder (AUD) criteria, as measured by proton…
- Trial name
- NCT03418623
- Testing
- GET73
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Laboratorio Farmaceutico Ct S.r.l.
Opioid Use Disorder
Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder
The purpose of this study is to measure safety and efficacy and to determine dose-response relationship for INDV-2000 in participants with moderate to severe Opioid Use Disorder (OUD) who are new to treatment, have recently…
- Trial name
- NCT06384157
- Testing
- INDV-2000
- Where
- 35 sites in United States
- Volunteers
- 300 people
- Sponsor
- Indivior Inc.
Substance Use Disorder (SUD)
Study to Confirm the AuthenTicity of Point of Care Urine samplEs Using Oral fluoreScein Sodium in adulTs With substancE Use Disorder (ATTESTED)
The purpose of this phase III, randomized, double-blind, placebo-controlled study is to confirm the authenticity of point-of-care urine samples in adult persons with substance use disorder using fluorescein sodium as a marker.
- Trial name
- ATTESTED (NCT07356349)
- Testing
- Fluorescein
- Volunteers
- 114 people
- Sponsor
- UpTru Inc.
Tobacco Use Disorder
Evaluation of the Efficacy of QUITOXIL® in Smoking Cessation
As part of post-marketing clinical monitoring and with a view to applying for the digital medical device Quitoxil® to be included on the LPPR list, this prospective, multicentre, controlled, randomised clinical trial aims to…
- Trial name
- NCT07722832
- Testing
- Quitoxil®, Nicotine Replacement Therapies
- Volunteers
- 606 people
- Sponsor
- KLAVA Innovation
Alcohol Abuse, Drug Abuse
A Web App for Patients With Alcohol and Drug Use Problems in Primary Care
The objective of this pilot study is to evaluate the feasibility and technical merit of a web application for patients in primary care called Check-up and Choices (CC).
- Trial name
- NCT01830114
- Testing
- Web app
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Behavior Therapy Associates, LLP
Chronic Pain, Pain
A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain
This Phase 2 study will evaluate whether multiple doses of cebranopadol suppress opioid withdrawal signs and symptoms compared with placebo in adults with chronic pain who are physically dependent on prescribed opioids.
- Conditions
- Chronic Pain, Pain, Opioid Withdrawal (Disorder), Opioid Use Disorder
- Trial name
- NCT07874620
- Testing
- Cebranopadol
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Adneuris Therapeutics, Inc.